| Company Name: | Cardiac Science Corporation | | Ticker Symbol: | CSCX | | | WWW Address: | www.quinton.com | | CEO: | David L. Marver | | No. of Employees: | 594 | | Common Issue Type: | CS | | Business Description: | The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 2.44 |  -0.23 | 2.44 | 2.48 | 2.71 | 2.78 | 2.65 | 91654 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 62.4 | 23.4 | 1.33 | -4.30 | 0.00 | 0.0 | 0.0 | 8.10 - 2.45 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 2.67 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 62.4 | mil |
| Latest Shares Outstanding | 23.4 | mil |
| Earnings pS (EPS) | -4.30 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 347,059 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 23.1 | mil |
| Float as % of Shares Outstanding | 98.8 | % |
| Foreign Sales | 81 | mil |
| Domestic Sales | 125 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 43.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 9.70 | % |
| Gross Profit Margin | 42.1 | % |
| EBITDA Margin | -11.2 | % |
| Pre-Tax Profit Margin | -79.1 | % |
| Assets Turnover | 0.8 | % |
| Return on Assets (ROA) | -137.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -266.3 | % |
| Current Ratio | 1.6 | |
| Leverage Ratio (Assets/Equity) | 1.9 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 1.46 | $ |
| Cash pS | 1.35 | $ |
| Book-Value pS | 2.80 | $ |
| Tangible Book-Value pS | 1.57 | $ |
| Cash Flow pS | -7.19 | $ |
| Free Cash Flow pS | -0.13 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.95 | |
| Price/Tangible Book Ratio | 1.70 | |
| Price/Cash Flow | -0.4 | |
| Price/Free Cash Flow | -20.0 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -13.6 | 87 | 1,474 | 3,678 |
| 4 Weeks | 3.95 | 2.65 | 3.85 | -30.6 | 69 | 976 | 19,520 |
| 13 Weeks | 4.15 | 2.65 | 3.06 | -12.7 | 82 | 712 | 45,599 |
| 26 Weeks | 4.83 | 2.65 | 3.35 | -20.3 | 65 | 829 | 105,251 |
| 52 Weeks | 8.10 | 2.45 | 5.50 | -51.5 | 36 | 789 | 197,931 |
| YTD | 7.88 | 2.45 | - | -64.4 | 29 | 808 | 181,777 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 2.80 | 3.01 | 3.61 | 3.65 | 3.60 | 1.33 | 1.24 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 4.76 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 58.91 |
| R&D | 0.00 | NA | 14.19 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -26.1 | -28.0 | 13.2 |
| Earnings % | -100.0 | -100.0 | -100.0 |
| EPS % | -100.0 | -100.0 | -100.0 |
| EPS $ | -3.27 | -2.96 | -4.67 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 37.93 |
| Current Ratio | 2.7 |
| Quick Ratio (Acid Test) | 1.7 |
| Liquidity Ratio (Cash) | 0.91 |
| Receivables Turnover | 6.7 |
| Average Collection Period | 54 |
| Working Capital/Equity | 49.0 |
| Working Capital pS | 2.81 |
| Cash-Flow pS | -4.00 |
| Free Cash-Flow pS | 0.57 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.00 |
| Financial Leverage Ratio (Assets/Equity) | 1.3 |
| Debt Ratio | 22.6 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.4 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.87 |
| Tobin's Q Ratio | 0.37 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | 3.48 |
| Enterprise Value (EV)/Free Cash Flow | 17.98 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 1.70 |
| Price/Book Ratio - LTM | 0.95 |
| Price/Cash Flow Ratio | -0.4 |
| Price/Free Cash Flow Ratio - LTM | -20.0 |
| Price/Sales Ratio | 0.38 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 13.4 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.65 |
| Tangible Book Value pS - LTM | 1.57 |
| Book Value pS - LTM | 2.80 |
| Capital Invested pS | 5.64 |
| Cash pS - LTM | 1.35 |
| Cash Flow pS - LTM | -7.19 |
| Free Cash Flow pS - LTM | -0.13 |
| Earnings pS (EPS) | -4.30 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 6.31 |
| Free Cash Flow Margin 5YEAR AVG | 3.85 |
| Net Profit Margin | -47.7 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 1.57 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.57 |
| Return on Capital Invested (ROCI) | -74.7 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 1.00 |
| Return on Assets (ROA) | -57.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 42.1 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | -11.2 |
| EBIT Margin - LTM | -79.1 |
| Pre-Tax Profit Margin | -45.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | -4.4 |
| Effective Tax Rate - 5YEAR AVRG. | 46.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 141 |
| Revenue per Employee | 347,059 |
| Net Income per Employee | -165,630 |
| Average Collection Period | 55 |
| Receivables Turnover | 6.7 |
| Day's Inventory Turnover Ratio | 86 |
| Inventory Turnover | 4.2 |
| Inventory/Sales | 12.0 |
| Accounts Payble/Sales | 6.17 |
| Assets/Revenue | 1.00 |
| Net Working Capital Turnover | 3.19 |
| Fixed Assets Turnover | 3.05 |
| Total Assets Turnover | 1.0 |
| Revenue per $ Cash | 5.95 |
| Revenue per $ Plant | 29.48 |
| Revenue per $ Common Equity | 1.57 |
| Revenue per $ Capital Invested | 1.57 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 35.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 8.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 8.0 |
|
|  
|
| |
 |  |